Chaib M, Sipe LM, Yarbro JR, Bohm MS, et al. PKC agonism restricts innate immune suppression, promotes antigen cross-presentation and synergizes with agonistic CD40 antibody therapy to activate CD8(+) T cells in breast cancer. Cancer Lett 2022 Jan 21. pii: S0304-3835(22)00025.
PMID: 35074498